School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Pulmonx Corp LUNG

Healthcare · Health Care

$1.84last close 2026-10-09 · market cap $79.02M · delayed data

Trailing returns

1M-7.07%
3M+25.17%
6M+35.29%
1Y+6.36%
5Y-95.19%

Basis: Adjusted daily closes.

What it does

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Open LUNG in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies